Low estrogen levels in postmenopausal hypertension are linked to metabolic reprogramming and aortic tissue changes, with L-alpha-aminobutyric acid emerging as a potential protective biomarker.
Structure-based designed chalcone and pyrazoline derivatives inhibited the ELF3-MED23 protein-protein interaction, leading to HER2 downregulation and retardation of tumor growth in HER2-positive gastric cancer.